Integrated Molecular Risk Stratification and Measurable Residual Disease-Guided Consolidation Improve Outcomes in Pediatric Non-Down Syndrome Acute Megakaryoblastic Leukemia.
Young children with a rare blood cancer had better survival when doctors used blood tests to guide transplant timing and treatment intensity decisions.
In 58 pediatric non-DS-AMKL patients treated with FLAG-IDA induction, MRD-guided consolidation and HSCT in first complete remission for high-risk patients significantly improved overall and event-free survival. The study confirms inferior outcomes for this rare AML subtype versus other AML subtypes and highlights MRD as a critical decision tool for transplant timing.
What the study was
- Study design
- Multicenter retrospective cohort
- Population
- Pediatric patients with non-Down syndrome acute megakaryoblastic leukemia (non-DS-AMKL) in China
- Sample size
- 58
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cancer Medicine
Why it surfaced
Rare pediatric AML subtype (non-DS-AMKL) with high unmet need; multicenter Chinese cohort with MRD-guided decision data; retrospective design and moderate n limit generalizability.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.